Though type I interferons (IFNs), including IFN-α, have been used in the clinical treatment of HCC to improve overall survival and delay tumor progression, clinical trials have revealed its limited effectiveness due to the high reported toxicity (3, 4, 5). This evidence concerns the gene IFNA1 and neoplasm.